BioNTech (BNTX) and OncoC4 have had a partial clinical hold placed by the FDA on a Phase 3 study for BNT316/ONC-392 in the ...

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing ...

BioNTech (NASDAQ:BNTX) shares fell Friday after the company said it had been informed by partner OncoC4 that FDA placed partial clinical hold on Phase 3 study of BNT316/ONC-392 (gotistobart) in ...

The new biotech will operate under OncoC4’s name and will continue to be led by CEO Liu. Specific financials of the deal were not disclosed. BioNTech's cancer push continues, coughing up $200M ...

In March 2023, OncoC4 announced a strategic collaboration with BioNTech to co-develop and commercialize ONC-392 in multiple solid tumor indications. OncoC4 received $200M upfront and is eligible ...

BioNTech is the Marketing Authorization Holder ... Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron.

Omicron KP.2 variant adapted vaccine COMIRNATY is now authorized in Canada for individuals 6 months of age and older. It is expected to be available in Canada in the coming ...

Omicron KP.2 variant adapted vaccine COMIRNATY is now authorized in Canada for individuals 6 months of age and older. It is expected to be available in Canada in the coming weeks. The updated ...

OncoC4, Pfizer and Regeneron. For more information, please visit www.BioNTech.com. BioNTech Forward-looking Statements This press release contains forward-looking statements within the meaning of ...